Ranbaxy-Teva profit sharing for Lipitor generic: just plan B or a three-way pattern?
This article was originally published in Scrip
Executive Summary
Was Ranbaxy's profit-sharing deal with Teva Pharmaceutical Industries for generic Lipitor (atorvastatin) simply part of a fall-back strategy to ensure a day one launch in the US, or is it part of a gameplan modelled along the lines on Ranbaxy's strategy to monetise 180-day exclusivity of generic Flomax (tamsulosin), when it failed to get launch approval on time?